Complete Trisomy 21 Syndrome
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Trisomy 21 in patients with DS results in increased activity of an important antioxidant enzyme Cu/Zn superoxide dismutase (SOD) which gene is located on the 21st chromosome along with other proteins such as transcription factor Ets-2, stress inducing factors (DSCR1) and precursor of beta-amyloid protein responsible for the formation of amyloid plaques in Alzheimer disease.
|
24908086 |
2014 |
Complete Trisomy 21 Syndrome
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
ETS2 rs461155 showed high heterozygosity in DS.
|
22048266 |
2011 |
Complete Trisomy 21 Syndrome
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Recent work with the Ts65Dn model of DS, which has orthologues of about 50% of the genes on chromosome 21 (Hsa21), has indicated that three copies of the ETS2 (ref.
|
20535211 |
2010 |
Complete Trisomy 21 Syndrome
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
These results suggest that ETS2 expression is linked to the biology of AMkL in both DS and non-DS children, and that ETS2 acts by regulating expression of hematopoietic lineage and transcription factor genes involved in erythropoiesis and megakaryopoiesis, and in chemotherapy sensitivities.
|
18094719 |
2008 |
Complete Trisomy 21 Syndrome
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
These results highlight DS as a model to understand the role of APOE4 allele in unsuccessful ageing considering that a number of proinflammatory supernumerary genes (Cu/Zn superoxide dismutase, Ets-2 transcription factors, Down syndrome critical region 1, stress-inducible factor, interferon-alpha receptor and the amyloid precursor protein) are located on chromosome 21 and are implied in the pathologic processes of DS.
|
17559337 |
2007 |
Complete Trisomy 21 Syndrome
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Ets-2 and DSCR1 overexpression in DS has been linked to cell degeneration.
|
17168651 |
2006 |
Complete Trisomy 21 Syndrome
|
0.100 |
Biomarker
|
disease |
BEFREE |
Strong ets-2 immunoreactivity was observed in DS/AD and sporadic AD brains associated with degenerative markers such as bax, intracellular Abeta, and hyperphosphorylated tau.
|
15745955 |
2005 |
Complete Trisomy 21 Syndrome
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The DS-CHD candidate region has been suggested to span between PFKL and D21S3, which is the STS marker near the ETS2 loci.
|
15063784 |
2004 |
Complete Trisomy 21 Syndrome
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Indeed we report for the first time that the ETS2 overexpression transgenic mouse develops a smaller thymus and lymphocyte abnormalities similar to that observed in DS.
|
12554679 |
2003 |
Complete Trisomy 21 Syndrome
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Our data therefore suggest that overexpression of ETS2 may contribute to the increased rate of apoptosis of neurons in Down syndrome.
|
14678752 |
2003 |
Complete Trisomy 21 Syndrome
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
We conclude that ETS2 is a transcriptional regulator of beta-APP and that overexpression of ETS2 in DS may play a role in the pathogenesis of the brain abnormalities in DS and possibly AD.
|
12890557 |
2003 |
Complete Trisomy 21 Syndrome
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Here we show that Ets-2, a transcription factor located on human chromosome 21 and already overexpressed in multiple tissues in Down syndrome (DS, trisomy 21), is induced by low concentrations of hydrogen peroxide.
|
11573964 |
2001 |
Complete Trisomy 21 Syndrome
|
0.100 |
Biomarker
|
disease |
BEFREE |
Subsequent densitometric analysis of APP and ETS-2 immunoreactivity did not produce any significant change between controls and DS.
|
11771756 |
2001 |
Complete Trisomy 21 Syndrome
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
These results indicate that Ets2 has an important role in skeletal development and that Ets2 overexpression in transgenics is responsible for the genesis of the same type of skeletal abnormalities that are seen in Down's syndrome.
|
11175361 |
2000 |
Complete Trisomy 21 Syndrome
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
This is the first report to clearly show that no overexpression of ets-2 can be found in heart of patients with DS, thus providing evidence against the current gene dosage effect-hypothesis.
|
9918849 |
1999 |
Complete Trisomy 21 Syndrome
|
0.100 |
Biomarker
|
disease |
BEFREE |
Decreased ETS2 transcripts found in temporal and frontal lobe of patients with Down Syndrome, however, may be involved in the pathogenesis of Down Syndrome including specific neurodegenerative processes and deteriorated plasticity of the brain taking place in Down Syndrome brain, as the concerted action of transcription factors may be seriously impaired.
|
10666682 |
1999 |
Complete Trisomy 21 Syndrome
|
0.100 |
Biomarker
|
disease |
BEFREE |
In an effort to contribute to the construction of a transcriptional map of the DS CHD region we have performed direct cDNA selection using a YAC contig that maps between ETS2 and D21S15 and cDNAs synthesised from fetal heart structures.
|
9544840 |
1998 |
Complete Trisomy 21 Syndrome
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
The authors hypothesize that an excess of luteinizing hormone and follicle-stimulating hormone gonadotropins and overexpression of the Ets-2 gene through gene dosage effect could predispose patients with DS to the development of TGCT.
|
9307193 |
1997 |
Complete Trisomy 21 Syndrome
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Our results indicate that Ets2 has a role in skeletal development and implicate the overexpression of Ets2 in the genesis of some skeletal abnormalities that occur in Down's syndrome.
|
8596630 |
1996 |
Complete Trisomy 21 Syndrome
|
0.100 |
Biomarker
|
disease |
BEFREE |
New chromosome 21 DNA markers isolated by pulsed field gel electrophoresis from an ETS2-containing Down syndrome chromosomal region.
|
1483701 |
1992 |
Complete Trisomy 21 Syndrome
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
ETS-2 expression appeared to be slightly increased in Down syndrome brain compared with that of normal controls of the same gestational age.
|
2529204 |
1989 |
Complete Trisomy 21 Syndrome
|
0.100 |
Biomarker
|
disease |
BEFREE |
In addition, the role of c-ets-2 in cell proliferation and its location in the minimal Down syndrome region on chromosome 21 implicates its involvement in the phenotypic changes associated with Down syndrome.
|
2813360 |
1989 |
Complete Trisomy 21 Syndrome
|
0.100 |
Biomarker
|
disease |
BEFREE |
Molecular genetic analysis of Down syndrome (DS) patients with partial trisomy 21 allowed us to reinforce the supposition that ETS2 may be a gene of the minimal DS genetic region.
|
2902635 |
1988 |
Complete Trisomy 21 Syndrome
|
0.100 |
Biomarker
|
disease |
BEFREE |
Genetic mapping of Prm-1, Igl-1, Smst, Mtv-6, Sod-1, and Ets-2 and localization of the Down syndrome region on mouse chromosome 16.
|
2882955 |
1987 |
Complete Trisomy 21 Syndrome
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Because a small region of chromosome 21 containing the ets-2 gene is duplicated in patients with Alzheimer's disease, as well as in karyotypically normal Down syndrome, duplication of a subsection of the critical segment of chromosome 21 that is duplicated in Down syndrome may be the genetic defect in Alzheimer's disease.
|
2950593 |
1987 |